Antibacterial resistance in Streptococcus pyogenes ( GAS) from healthy carriers and tonsillitis patients and association with antibacterial sale in the Faroe Islands

• Published in: APMIS
• Main Authors: Magnussen, Marita D., Gaini, Shahin, Gislason, Hannes, Kristinsson, Karl G.
• Other Authors: Faroese Research Council, BP Amoco, Chevron Texaco, Eik Vísindagrunnurin
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2016
• Subjects: Faroe Islands; Iceland
• Online Access: http://dx.doi.org/10.1111/apm.12513; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fapm.12513; https://onlinelibrary.wiley.com/doi/pdf/10.1111/apm.12513

The aim of this study was to investigate the antibacterial resistance of Streptococcus pyogenes ( GAS ), and correlate the findings with the sales of erythromycin and tetracycline. General practitioners in the Faroe Islands were recruited to send oropharyngeal swabs. From an ongoing pneumococcal study, nasopharyngeal swabs were sampled from healthy children 0–7 years of age. Erythromycin susceptibility data from Iceland were obtained from the reference laboratory at the Landspitali University Hospital. Susceptibility testing in the Faroe Islands and Iceland was performed according to CLSI methods and criteria. The resistance rate to erythromycin and tetracycline found in patients in the Faroe Islands in 2009/2010 was 6% and 30% respectively. Tetracycline resistance in patients declined significantly from 2009 to 2010 (37–10%, p‐value = 0.006 < 0.05) and differed significantly between age groups (p‐value = 0.03 < 0.05). In Iceland, there was a peak in erythromycin resistance in 2008 (44%) and a substantial decrease in 2009 (5%). Although the prevalence of erythromycin and tetracycline resistance in the Faroe Islands and Iceland may be associated with antimicrobial use, sudden changes can occur with the introduction of new resistant clones.